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Abstract
Neural degeneration and regeneration are important topics in neurological diseases. There are limited
options for therapeutic interventions in neurological diseases that provide simultaneous spatial and
temporal control of neurons. This drawback increases side effects due to non-specific targeting.
Optogenetics is a technology that allows precise spatial and temporal control of cells. Therefore, this
technique has high potential as a therapeutic strategy for neurological diseases. Even though the
application of optogenetics in understanding brain functional organization and complex behaviour states
have been elaborated, reviews of its therapeutic potential especially in neurodegeneration and regeneration
are still limited. This short review presents representative work in optogenetics in disease models such as
spinal cord injury, multiple sclerosis, epilepsy, Alzheimer’s disease and Parkinson’s disease. It is aimed to
provide a broader perspective on optogenetic therapeutic potential in neurodegeneration and neural
regeneration.
Keywords: light-activated proteins, neural plasticity, spinal cord injury, epilepsy, Parkinson's disease,
Alzheimer's disease, multiple sclerosis, neural engineering, memory retrieval, neuron inhibition, neuron
activation, neural regeneration
Introduction
Optogenetics is a technology that combines optics with genetics to induce a precise gain or loss-of-
function in cells or tissue by applying light (Yizhar et al., 2011a). This biological technique involves: 1)
engineering a gene that must be delivered in a cell specific manner and expressed at adequate levels, 2)
developing a mode to deliver light for in vitro and in vivo studies, and 3) detecting the effect of
optogenetics (i.e., dendritic density, immunofluorescence, electrophysiology, behaviour studies) (Yizhar et
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and millisecond precision control of neurons (Deisseroth et al., 2006; Deisseroth, 2011). Accurate spatial
and temporal control is especially important to a system as complex as the nervous system, containing a
network of billions of cells.
Current methods for neurological treatment involve targeting the nervous system with deep brain
stimulation (DBS) and pharmacologic therapy (Oluigbo et al., 2012; Connolly and Lang, 2014). While
DBS provides precise temporal control of neurons, it lacks spatial specificity. On the other hand,
pharmacologic therapy can give spatial specificity, but it lacks temporal control of cellular processes (Li et
al., 2012). Consequently, it is challenging for the neuroscience field to create a technique with these dual
features. In the early 1970s, Francis Crick postulated that the field of neuroscience needed a tool that could
be used to control neurons with cellular and temporal precision (Crick, 1979). Crick suggested light
activation of neurons may be the solution to these drawbacks. It took nearly three decades to achieve what
he had envisioned with the introduction of optogenetics to the study of the nervous system (Boyden et al.,
2005). This review aims to briefly, yet concisely, introduce optogenetics and summarize its use as a tool to
understand pathological circuitry and a possible treatment for neurological diseases.
Major Components of Optogenetics
Optogenetics works by transducing light-stimulated electrical currents directly into specific cells (Terakita,
2005). To achieve this purpose, this technique is comprised of three major components: 1) light-activated
proteins, 2) light, and 3) mode of delivery.
Light-activated proteins
Light-activated proteins were first discovered approximately 40 years ago. There was the discovery of
bacteriorhodopsin (proton pump) in 1971, halorhodopsin (chloride pump) in 1979 (Oesterhelt and
Stoeckenius, 1971; Matsuno-Yagi and Mukohata, 1977), and channelrhodopsin-1 (proton channel) and -2
(cation channel) in 2002 and 2003 (Nagel et al., 2002, 2003), respectively. These channels and pumps
called opsins are microbial 7-transmembrane domain proteins containing trans-retinal cofactors that are
activated upon light exposure. In general, these microbial opsins have the common characteristic of
directly inducing electrical currents into cells upon light activation. This feature is different from
rhodopsin (opsin found in the retina of vertebrates), which indirectly transduces electrical current via
intracellular G-proteins (Oesterhelt and Stoeckenius, 1971; Stryer, 1986).
Despite their common role as cellular electrical transducers, each of these prokaryotic opsins brings about
different effects on membrane potential upon activation with light. Upon light-induced electrical
transduction, some opsins such as halorhodopsin (HR) hyperpolarize the membrane potential whereas
other opsins such as channelrhodopsin (ChR) depolarize the membrane potential (Figure 1) (Zhang et al.,
2006). Halorhodopsin hyperpolarizes the membrane potential by pumping chloride ions into cells,
resulting in spiking and neurotransmission inhibition, and ChR depolarizes cell membranes by allowing
cations to diffuse into the cells by an electrochemical gradient, which could induce an action potential
(Nagel et al., 2003; Kikukawa et al., 2015). This is especially applicable in neurons because of their
electrophysiological properties of generating action potentials.
Initially, although the optogenetics method seemed revolutionary, there was a lot of scepticism about its
application in neuroscience. There were concerns about whether photocurrents, which are currents induced
by photons, would be too weak and slow to activate and inactivate neurons with millisecond precision.
Moreover, it was thought that opsins may be toxic or not expressed at high enough levels in neurons to
mediate a desired effect. Since opsins require trans-retinal cofactors for activation, it was postulated that
optogenetics would require a multicomponent delivery similar to the novel molecular strategies, which
were engineered at the time (Zemelman et al., 2002; Banghart et al., 2004; Deisseroth, 2011).
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The challenges of optogenetics application in neuroscience were overcome by Boyden et al. in 2005
(Boyden et al., 2005). Boyden’s group delivered the first opsin into neurons by transfecting cultured
hippocampal cells with lentivirus containing channelrhodopsin-2 (ChR2). In their study, they showed
activation of neurons within milliseconds of light stimulation, synaptic neurotransmission, and neuronal
spike trains resembling normal neuron electrophysiology. A significant observation was that cell health
and electrophysiology properties were not affected by ChR2 expression. Furthermore, since retinoids were
found present in sufficient amounts in mature mammalian brains, this conferred optogenetics as a single-
component strategy to control neuronal activity (Deisseroth et al., 2006; Zhang et al., 2006).
Complementary tools that could inhibit neuronal activity were then introduced following the discovery of
natronobacterium pharaonic halorhodopsin (NpHR) (Han and Boyden, 2007) and a new class of inhibitory
opsins called archaerhodopsin, which are outward proton pumps (Chow et al., 2010).
Since the serendipitous application of optogenetics to neural systems, the field has vastly expanded
(Boyden, 2011). However, the introduction of optogenetics to neuroscience has not been without its
challenges. For example, there were challenges in increasing the cell membrane transport of NpHR since it
was observed to accumulate intracellularly at high expression levels (Gradinaru et al., 2007). To increase
its cell surface expression, the C-terminal endoplasmic reticulum (ER) export peptide sequence from
Kir2.1 channel was added, which resulted in the synthesis of the opsin enhanced natronobacterium
pharaonic halorhodopsin (eNpHR) (Gradinaru et al., 2008). Moreover, NpHR was inefficient in inhibiting
neurons since it pumped one chloride ion per photon. The finding of high-resolution crystal structure of
ChR2 facilitated the reconstruction of its ion pore to conduct chloride ions instead of cations into the cell,
which changed its properties to a neuron inhibitory channel and created a more efficient inhibitory opsin
(Kato et al., 2012; Berndt et al., 2014; Wietek et al., 2014). NpHR also had a slow recovery rate from the
inactivated state upon continuous stimulation, which was unfavourable to its application in neurons
(Hegemann et al., 1985; Bamberg et al., 1993). High-throughput screening enabled the discovery of a new
inhibitory opsin called archaerhodopsin-3 (outward proton pump) that mediates strong currents and
spontaneously recovers from light-induced inactivation (Chow et al., 2010). With advanced understanding
of opsin kinetics, structure, molecular trafficking, and optical properties, it has been possible to optimize
their properties (e.g., increase membrane expression, light sensitivity, and expression safety) or modify
them for diverse applications (e.g., slower or faster closing and/or opening kinetics, shifting wavelength of
activation) (Zhang et al., 2008; Lin et al., 2009; Gradinaru et al., 2010; Gunaydin et al., 2010; Boyden,
2011).
Light
A major component in optogenetics is the light wavelength to activate a specific opsin. For example, ChR2
is activated by ~460 nm light and NpHR is activated by ~570 nm light. This allows the coexpression of
these opsins into a neuron or more complex system to simultaneously activate and inactivate neurons
(Matsuno-Yagi and Mukohata, 1977; Nagel et al., 2003). Since these two opsins work antagonistically
(i.e., ChR2 activates neurons; NpHR inactivates neurons), this strategy would not be suitable if one is
interested in synergistically activating two different groups of neurons. Zhang et al. addressed this issue by
identifying and characterizing a cation-conducting channelrhodopsin (VChR1) with red-shifted absorption
spectrum and maximum absorption wavelength ~70 nm higher than ChR2 (531 nm) (Zhang et al., 2008).
Since ChR2 and VChR1 both depolarize membrane potentials and are activated by different wavelengths,
it is possible to simultaneously activate different groups of neurons within a neural circuit.
One of the challenges of optogenetics is targeting deeper brain structures while minimizing invasiveness of
implanting optical fibers to deliver light. A strategy to overcome this is to develop opsins with red-shifted
activation wavelengths. This will reduce light scattering and allow deeper light penetration (Figure 2B)
(Pansare et al., 2012). Recent developments in opsin engineering to address this issue include the cation
channels (activation wavelengths): red-activatable ChR (ReaChR) (~590–630) (Lin et al., 2013);
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Channelrhodopsin-1/Volvox Channelrhodopsin (C1V1; E122T mutation; ChR1/VChR1 chimera) (~600
nm) (Yizhar et al., 2011b); Chrimson (~660 nm) (Klapoetke et al., 2014); fast red-activatable
Channelrhodopsin (bReaChES) (~590 nm) (Kim et al., 2016); Volvox Channelrhodopsin (VChR1; similar
to channelrhodopsin-1) (~531 nm) (Zhang et al., 2008) and the chloride pump Jaws (~635 nm) (Chuong et
al., 2014). Moreover, the ChR2 gene has been modified to produce a “bistable” channel also known as
step-function opsin (SFO). This channel is opened by one wavelength and closed by a different
wavelength. This allows control of how long a channel can stay in the opened state (Berndt et al., 2009).
Since these channels can be kept open for longer periods of time, their conduction efficiency is higher,
which reduces the light intensity necessary to activate a neuron or other cells.
Mode of delivery
Opsin delivery
Similar to the genetically encoded GFP, opsins can be specifically delivered to a subset of cells. One of the
delivery methods used is transfection of lentivirus or adeno-associated virus (AAV) packaged with the
opsin gene, a marker such as enhanced green fluorescent protein (EGFP) or enhanced yellow fluorescent
protein (EYFP) and a cell-specific promotor (e.g., calcium/calmoduluin-dependent protein kinase II alpha
(CaMKIIα) promotor for excitatory neurons, glial fibrillary acidic protein (GFAP) promoter for astrocytes,
and preprohypocretin/preproorexin (ppHcrt) promotor for hypocretin neurons). Another method includes
using transgenic mice to create a uniform expression of the opsin in a specific group of cells (Zhang et al.,
2010; Adamantidis et al., 2014). However, some cells (e.g., parvalbumin interneurons, dopaminergic
neurons) contain promotors with weak transcriptional activity, which makes it difficult to express opsins in
a cell-specific manner at necessary levels on the cell membrane. To overcome this, conditional expression
systems using Cre recombinase-locus of crossover in P1 (Cre-loxP) are used to increase the expression of
opsins in these cells (Atasoy et al., 2008; Kuhlman and Huang, 2008; Yizhar et al., 2011a). Briefly,
transgenic mice are engineered to express Cre recombinase in a cell-specific manner (e.g., in PV
GABAergic neurons). A vector containing an upstream ubiquitous promotor, a stop cassette flanked by
unidirectional lox-P and a downstream opsin gene is then delivered to the region of interest. In this
manner, cells that uptake the vector but do not express Cre recombinase will not be able to express the
opsin because of the stop cassette. However, cells containing Cre recombinase will excise the stop cassette
and allow high expression of opsin under the control of a ubiquitous transcription promoter (Zeng and
Madisen, 2012).
Light delivery
For in vitro studies, a laser or light emitting diode (LED) can be directly coupled to the microscope light
path (Zhang et al., 2010). For in vivo optogenetic stimulation of superficial layers of the cortex (e.g., layer
5 of primary motor cortex), small LED bulbs can be implanted on thinned skull directly above the target
region (Gradinaru et al., 2007; Huber et al., 2008). However, since light power density drops to as low as
1% upon 1 mm penetration of tissue, a fiber-optic-based optic neural interface has been developed in
which LED or laser diode systems can be coupled to lightweight flexible optic fibers to deliver light to
deeper brain tissue (Figure 2C) (Adamantidis et al., 2007; Aravanis et al., 2007).
One of the challenges in neuroscience research is to observe how neural activity results in behaviour
changes. This requires the in vivo recording of neural activity, which was previously done with
conventional 1 or 2-photon imaging. However, previous methods required the stereotaxic stabilization of
the head, which prevents studying freely moving animals and cannot image deep structures such as the
hippocampus and amygdala (Doronina-Amitonova et al., 2013; Gunaydin et al., 2014). To overcome this
issue, fiber-optic imaging/recording systems, which involve fluorescence modalities such as: 2-photon,
scanning confocal fluorescence, and epifluorescence have been developed (Helmchen et al., 2001;
Flusberg et al., 2005; Sawinski et al., 2009). Coupled with optogenetics technology, it is possible to
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simultaneously stimulate and record intracellular Ca , electrical activity, and/or fluorescent proteins in
specific groups of neurons in any brain structure and observe the resulting behaviour in freely moving
animals (Gradinaru et al., 2007; Miyamoto and Murayama, 2016). Szabo et al. made this possible by
coupling a microscope to a fiber bundle containing a micro-objective to activate neurons and
simultaneously image and record their activity (Szabo et al., 2014). This technology, which is called a
fiberscope, is capable of fluorescence imaging with epifluorescence, structured illumination, or scanless
multipoint confocal microscopy. Other developments have included the use of an optrode, which combines
an optic fiber with an electrode to simultaneously stimulate neurons and record their activity with single-
neuron resolution (Arenkiel et al., 2007; Tamura et al., 2012). Recent advances in light delivery have
implemented closed-loop circuits, which allow real-time control of neurons based on error of desired and
measured output, and wireless light stimulation, which does not require restraining animals during
placement of optical fibers (Grosenick et al., 2015; Montgomery et al., 2015; Park et al., 2015). Similarly,
a wireless optrode has been developed (Gagnon-Turcotte et al., 2017). These technologies provide a more
natural environment for optogenetic stimulation and neuron activity recording (Figure 2).
Application of Optogenetics in Neuroscience and Neurological Disorders
Optogenetics could be an invaluable tool in the field of neuroscience. It induces gain or loss of function in
neurons and behavior with precise control for quick and specific outcomes. Since its introduction for
neuroscience application in 2005 (Boyden et al., 2005), this light-sensitive technology has vastly improved
our understanding of treatment mechanism, pathology of neurological disease, neural circuitry, and
physiological processes. It has been used to advance our understanding of complex processes such as:
learning (Schroll et al., 2006), sleep (Adamantidis et al., 2007), vision (Farah et al., 2007), addiction
(Witten et al., 2010), and movement (Chen et al., 2014; Proville et al., 2014). Moreover, it has been used to
find new targets for therapy. Thus, optogenetics is a powerful tool in basic science research.
One of the challenges of optogenetics is its translatability to the clinic. Opsin gene delivery is invasive,
since it would require injecting viruses into nervous tissue. Delivering light to deep brain regions would
require optic fiber implantation, which may cause direct trauma. Moreover, applying light to the brain may
cause heat damage. However, once these problems are overcome, optogenetics can be another tool to treat
neurological diseases. Applying optogenetics to several neurological disease models such as spinal cord
injury, epilepsy, Alzheimer’s disease (AD) and Parkinson’s disease (PD) may provide an alternative
treatment with less side effects than current therapies. The nervous system is made up of complex neural
networks that work with spatial and temporal precision. Therefore, the ideal treatment would restore
normal physiology, and optogenetics is a capable tool. In the following session, we will focus on the
application of optogenetics in these diseases and discuss the challenges of translating this technique to the
clinic.
Spinal cord injury
Spinal cord injury (SCI) is a devastating traumatic event disconnecting the brain to the peripheral nervous
system (PNS). Patients may suffer from urinary and bowel incontinence, sexual dysfunction, and
sensorimotor paralysis (Furlan et al., 2011; Simpson et al., 2012). It is a global health problem with an
estimated prevalence in the range of 236–1,009 per million and costing a patient up to $1 million in the
first year and $185 thousand every year thereafter (Cripps et al., 2011; NSCISC, 2016). Although many
research efforts have advanced our understanding of pathophysiological mechanisms, new treatments have
been inadequate. Unlike the PNS, the adult mammalian central nervous system (CNS) is unable to
regenerate. Two mechanisms are recognized that prevent axonal regeneration in the CNS: 1) the
environment following injury is inhibitory for axonal regeneration (Yiu and He, 2006; Fitch and Silver,
2008; Hackett and Lee, 2016), and 2) neurons do not have sufficient intrinsic capacity to regenerate (He
and Jin, 2016).
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Optogenetics is an intriguing treatment for SCI, and applying optogenetics in SCI regeneration studies has
just been emerging. Upon axonal injury, there is an increase in intracellular calcium (Ziv and Spira, 1995,
1997). Calcium serves a multitude of purposes following injury including: regulating gene expression
through mitogen-activated protein kinase (MAPK) and Ca /calmodulin-dependent protein kinase
(CaMK) phosphorylation of cAMP response element binding protein (CREB); activating proteases to
cleave spectrin to reduce membrane tension; promoting vesicle fusion to the plasmalemma via Ca
dependent SNARE protein association; activating delta-like 1 homolog (DLK1) to promote retrograde
signalling to the soma; and stimulating growth cone formation to promote neural regeneration Figure 3
(Ziv and Spira, 1997; Deisseroth et al., 1998; Wu et al., 2001; Kamber et al., 2009; Ghosh-Roy et al.,
2010; Watkins et al., 2013; Hendricks and Shi, 2014). Further increase in intracellular calcium occurs
through action potentials, which are induced by retrograde membrane depolarization following axon
transection via voltage-gated sodium channels (Mandolesi et al., 2004). This depolarization is crucial for
axon regeneration since studies have shown that blockade with tetrodotoxin (i.e., voltage-gated sodium
channel blocker) prevents neurite regeneration (Mandolesi et al., 2004). Furthermore, other studies have
shown that electrical stimulation of peripheral neurons enhances neurite elongation (Brushart et al., 2002;
Udina et al., 2008). However, electrical stimulation of axotomized rubrospinal neurons (i.e., CNS neurons)
has failed to show enhancement of neurite outgrowth (Harvey et al., 2005). This may be due to the
counteracting molecules in the CNS such as myelin-associated inhibitors and chondroitin sulfate
proteoglycans (CSPGs), which inhibit regeneration (Yiu and He, 2006). Interestingly, expression of
constitutively active CREB in DRG neurons was sufficient to overcome myelin-associated inhibitors of
axon regeneration in spinal cord axons (Gao et al., 2004). However, calcium levels are likely inadequate to
alter gene expression into a regenerative state through CREB following CNS injury, since intracellular
calcium elevation is transient and not significantly different than those observed during physiological burst
activities (Friel and Chiel, 2008; Rishal and Fainzilber, 2010). Therefore, optogenetics using ChR2 for
induction of membrane depolarization and action potentials to enhance the elevation of intracellular
calcium following injury is a possible treatment option for SCI. Moreover, ChR2 is permeable to calcium
ions, so it would also directly increase intracellular calcium (Nagel et al., 2003).
Optogenetics has been used to treat respiratory dysfunction in Sprague-Dawley rats following cervical SCI
by transfecting spared motor neurons that have lost their presynaptic input. In this study, intermittent
optogenetic stimulation of the phrenic motor neuron pool following cervical 2 (C2) spinal hemisection
resulted in return to normal hemidiaphragm electromyography (EMG) activity in synchrony with the non-
lesioned side (Alilain et al., 2008). Interestingly, long periods of intermittent stimulation caused long-
lasting return of rhythmic diaphragm activity even after stimulation ceased. This was not observed in
control animals, indicating optogenetic stimulation induced neuroplasticity. To support this, optogenetics
has been shown to induce synaptic plasticity by long-term potentiation (LTP) of neurons in the
hippocampus (Zhang and Oertner, 2007). Neuroplasticity is of paramount importance for recovery
following SCI as spared pathways can be recruited to replace damaged axons (Sandrow-Feinberg and
Houlé, 2015). Furthermore, neuron electrical activity, which can be augmented with optogenetics, has been
shown to increase proliferation and differentiation of oligodendrocyte and neuron precursor cells, increase
myelin thickness, and enhance motor skill in mice (Gibson et al., 2014).
Optogenetics has also been studied in another type of CNS injury, stroke, which is similar to SCI in which
there is neuronal death and scar tissue formation (Choudhury and Ding, 2016). In a study by Cheng et al.
(2014), stimulation of layer 5 primary cortex with ChR2 in the region immediately adjacent to the stroke
lesion resulted in significant increase in neuroplasticity markers, cerebral blood flow, rotating beam test
performance and weight gain (Figure 4). Similarly, a different study showed optogenetic stimulation of
transplanted neural stem cells containing ChR2 promoted motor function recovery, increased expression of
neural plasticity markers, and downregulated transcription of pro-inflammatory genes in a stroke model
(Daadi et al., 2016). More recently, optogenetic stimulation of the lateral cerebellar nucleus (LCN) in a
middle cerebral artery (MCA) stroke model improved mouse performance in rotator beam. This study also
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showed an increase in the neuroplasticity marker growth-associated protein 43 (GAP43) in the ipsilesional
cortex (Shah et al., 2017). The successful application of optogenetics for stroke recovery suggests its
therapeutic potential for SCI. Moreover, optogenetics has been combined with a flexible electrophysiology
recording probe to interrogate the normal neural circuitry in spinal cord for movement of hindlimbs (Lu et
al., 2017). This technology demonstrated feasible fiber probe integration into the spinal cord with minimal
trauma, which shows its potential application for circuitry restoration in SCI. In summary, optogenetics has
a potential to improve SCI through: 1) increasing intracellular calcium leading to activation of intrinsic
regeneration mechanisms, 2) enhancing neuroplasticity of spared axons, 3) promoting axon myelination,
and 4) restoration of normal circuitry. Whether optogenetics can promote regeneration of severed axons
and subsequently functional recovery in SCI animal models remains to be determined.
Multiple sclerosis
Multiple sclerosis (MS) is a progressive inflammatory demyelination disease affecting several tract fibers
of the CNS (Hauser and Oksenberg, 2006). Patients may present with a wide range of symptoms including,
but not limited to, optic neuritis, paraesthesia, motor weakness, and ocular movement dysfunction (e.g.,
internuclear opthalmoplegia). Treatments have focussed on anti-inflammatory agents to reduce
symptomatic episode duration, frequency, and severity (Goldenberg, 2012). However, current therapy is
only partially effective and contains several side effects. An intriguing therapy for MS is to increase
neuronal activity, which has been shown to increase myelination and oligodendrocyte proliferation with
electrical stimulation (Li et al., 2010). However, electrical stimulation is non-specific and can cause
several side effects. To overcome this, a previous study demonstrated the potential of optogenetics for MS
treatment. Using ChR2 optogenetic stimulation of the premotor cortex in mouse models, Gibson et al.
reported that enhanced neuronal activity increased axon myelin thickness and oligodendrocyte
proliferation (Figure 5A) (Gibson et al., 2014). Optogenetics was mainly used in this study as proof-of-
concept (i.e., enhancing neural activity increases myelination), establishing a target for MS treatment.
Since MS is a disease of demyelination, electrical stimulation and optogenetics are potential techniques to
use in this disease.
Epilepsy
Epilepsy is a disease characterized by neuron hyperexcitability causing recurrent seizures and affecting
about 50 million people worldwide (Banerjee et al., 2009). Current treatments include pharmacologic
targeting, vagus nerve stimulation, and DBS (Perucca and Tomson, 2011; Fisher, 2012; Orosz et al., 2014;
Schmidt and Schachter, 2014; Ben-Menachem et al., 2015). However, these treatments contain several side
effects including neurocognitive side effects and hypersensitivity reaction from pharmacotherapy and
hallucinations and memory impairment from DBS (Walia et al., 2004; Andrade et al., 2006; Girardeau et
al., 2009; Hessen et al., 2009; Yang et al., 2011). Moreover, resistance to pharmacotherapy is a major
concern (Picot et al., 2008). Another challenge is that traditional DBS requires continuous stimulation of
internal brain structures. Since seizures occur erratically with potentially long interictal periods, there is
unnecessary DBS that may contribute to the side effects observed (Hartikainen et al., 2014). To overcome
the continuous DBS, the closed-loop device NeuroPace RNS© System has been developed and approved
for use in medication-resistant partial onset seizures (Morrell, 2011; Morrell and Halpern, 2016). This
system detects seizure activity and ablates the seizure focus on-demand and has been shown to improve
quality of life and to have no effect on mood and cognition (Morrell and Halpern, 2016). Although this
device has temporal specificity, it lacks spatial specificity, which may alter normal brain regions (Li et al.,
2012). Optogenetics may be beneficial to circumvent this problem with its high temporal and spatial
resolution.
Optogenetics has been shown to be effective in vitro and in vivo. In a study by Tønnesen et al., in vitro
optogenetic inhibition of hippocampal principal cells of regions CA1 and CA3 in a pharmacoresistant
model was sufficient to reduce seizure activity (Tønnesen et al., 2009). Furthermore, in an in vivo model of
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neocortical epilepsy, which is commonly pharmacoresistant (Schuele and Luders, 2008), transfection and
inhibition of hyperexcitable cortical pyramidal neurons with halorhodopsin reduced seizure activity (
Figure 5B) (Wykes et al., 2012). Optogenetics has also shown efficacy in thalamocortical seizures
following stroke using halorhodopsin inhibition of neurons (Paz et al., 2013), temporal lobe epilepsy by
activation of parvalbumin positive gamma-aminobutyric acid (GABAergic) interneurons with
channelrhodopsin-2 (Krook-Magnuson et al., 2013), and for penicillin induced absence seizures by
inhibition of thalamic neurons with enhanced Natronomonas pharaonis halorhodopsin (eNpHR) (
Figure 5B) (Han et al., 2015). Moreover, optogenetics has opened insight into the role of the cerebellum in
modulating temporal lobe epilepsy. In a study by Krook-Magnuson et al., a closed-loop seizure device was
used to detect temporal lobe seizure activity and deliver light to lateral or midline cerebellar regions
containing ChR2 or NpHR expressing Purkinje cells (Krook-Magnuon et al., 2014). This study showed
that cerebellar-directed intervention can inhibit seizure activity and increase interictal period. Although
optogenetics has been shown effective for treating epilepsy in animal models, translating this into the
clinic is challenging, considering not all epilepsies are the same. To overcome this challenge, a study
showed optogenetic activation of the deep/intermediate layers of the superior colliculus suppressed
seizures originating from diverse networks including thalamocortical (absence), brainstem, forebrain
(complex partial), and forebrain plus brainstem (Soper et al., 2016). Therefore, this is an intriguing target
for clinical application.
Previous methods to decipher pathological neural circuitry in epilepsy include pharmacological stimulation
and glutamate photo-uncaging. However, these methods are limited by long latency in the former and
long-lasting effect and requirement of glutamate replenishing in the latter (Zemelman et al., 2003;
Shepherd and Svoboda, 2005; Jin et al., 2006; Zhang et al., 2012). Optogenetics overcomes these
limitations by its short evoked-potential latency period and fast “on-off” kinetics allowing for effective
neuron stimulation with millisecond interpulse intervals (Boyden et al., 2005). In studies by Meeren et al.
and Sorokin et al., optogenetics was used to understand the pathway responsible for generalized absence
seizures, which was previously questioned (Meeren et al., 2005; Sorokin et al., 2017). They found that
rhythmic synchronized spiking or phasic firing of thalamacortical neurons was necessary and sufficient to
induce synchronous spike wave discharge (SWD) and behaviour activity indicative of absence seizures.
Moreover, optogenetics was used to identify the mechanism of low-frequency DBS for the treatment of
temporal lobe epilepsy. The efficacy treatment was found to be through activation of glutamatergic
CaMKIIα-positive neurons in the entorhinal cortex, which then activate GABAergic principal cells in the
hippocampus to ablate seizure activity (Xu et al., 2016). In summary, optogenetics can be applied in
epilepsy research, especially as a tool to improve our understanding of pathophysiology of different types
of epilepsy.
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline
(Qiu et al., 2009) and the pathological markers: extracellular senile plaques made up of beta-amyloid
protein and intracellular neurofibrillary tangles (Kumar et al., 2015). Most of the research has focussed on
these pathological markers and memory dysfunction in later stages of AD (Selkoe, 2001, 2002; West and
Bhugra, 2015). However, studies have shown aberrant synaptic phenotypes (Terry et al., 1991; Jacobsen et
al., 2006), decreased dendritic spine density in the dentate gyrus, LTP impairment, and dysfunctional
perforant pathway input from the entorhinal cortex to the dentate gyrus in mouse models of memory
impairment prior to formation of senile plaques (Jacobsen et al., 2006). These findings have increased
interest in earlier stages of AD.
A recent study by Roy et al. showed that early memory deficits in AD are a result of aberrant memory
retrieval and not memory consolidation (Roy et al., 2016). In their study, early AD mouse models were
used by overexpressing the delta-9 variant of presinillin-1 in combination with the Swedish mutation of
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amyloid precursor protein. To deduce the mechanism of memory impairment, contextual fear conditioning
(CFC) was used. In their model, the unconditioned stimulus electric shock was paired with the chamber
“Context A”. This caused the conditioned response “freezing”. Placing control mice in “Context A”
elicited freezing response, but early AD mice did not freeze after placement in “Context A” because of
memory impairment. However, following optogenetic activation of engram cells (i.e., neurons holding
traces of specific memory) in the dentate gyrus with ChR2, mice responded with freezing even in a
different environment “Context B”. This showed that memory impairment in early AD is not the result of
impaired memory storage but dysfunctional memory retrieval. Moreover, this study also showed the
potential of neuron stimulation in the treatment of AD. As mentioned above, reduced dendritic spine
density in the dentate gyrus is observed in early AD. Remarkably, optogenetic induction of LTP between
the perforant path synapse and dentate gyrus engram cells recovered spine density to control levels, and
this correlated with improved long-term memory (Figure 5C) (Roy et al., 2016).
Optogenetics has been used to clarify the causal relationship between synaptic plasticity and memory
encoding, which was previously challenging to elucidate (Stevens, 1998). In a study by Nabavi et al.
(2014), memory from cued-fear conditioning was inactivated and reactivated by long-term depression
(LTD) and LTP, respectively. This was observed by conditioning mice to reduce lever pressing
(conditioned response; CR) by pairing the unconditioned stimulus (US) “foot shock” with blue light
stimulation (conditioned stimulus; CS) of oChIEF-(mammalian-codon optimized variant of ChIEF; ChIEF
is a variant of ChEF with isoleucine 170 mutated to valine); ChEF is a chimera of channelrhodopsin 1 and
2) expressing neurons in the medial geniculate nucleus projecting to the lateral amygdala, which is an
essential pathway for fear conditioning (Repa et al., 2001). After the training phase, mice showed reduced
lever pressing upon blue light stimulation, which indicated successful conditioning. Interestingly, pairing
light stimulus with the foot shock resulted in LTP, which was detected by measuring the ratio of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to N-methyl-D-aspartate (NMDA) receptor
influence in optogenetically driven synaptic responses in amygdala slices. Furthermore, optical induction
of LTD caused the loss of conditioned response to blue light stimulation, and this response was reactivated
by inducing optical LTP. Therefore, this study showed that memory can be inactivated and reactivated
using LTD and LTP, respectively, and clarified the causal relationship between these synaptic processes
and memory. Collectively, optogenetics was mainly used as a tool to elucidate memory encoding in animal
models. In addition, it was used as a proof-of-concept to show that stimulation of dentate gyrus engram
cells in AD mice restores spine density, which correlated with memory retrieval.
Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease affecting 1–2% of the population above 60 years.
It is characterized pathologically by loss of dopaminergic neurons in the substantia nigra pars compacta
(SNc) and clinically by bradykinesia, cogwheel rigidity, resting tremor, and shuffling gait (Lang and
Lozano, 1998; Tanner and Aston, 2000; Dauer and Przedborski, 2003). Current therapies have been
focussing on improving symptoms and quality of life but have not been successful in reversing the disease
progression (Connolly and Lang, 2014). The two main therapies used for PD are pharmacotherapy and
DBS. However, these therapies have many potential side effects such as: nausea, constipation, orthostasis,
psychosis, impulse control disorders, depression, and mania (Weintraub et al., 2006; Temel, 2010;
Connolly and Lang, 2014). Moreover, medication-associated resistance and dyskinesia may develop
following long-term therapy with levodopa, which is one of the most effective treatments for PD (Fahn,
2000; Aquino and Fox, 2015). DBS is an effective treatment option for patients with insufficient response
to pharmacotherapy and/or develop dyskinesia. However, this treatment is invasive since it requires a
surgical procedure to implant electrodes into deep brain nuclei (Okun, 2012). Moreover, since DBS
requires electrical stimulation, it is a non-specific targeting treatment (Li et al., 2012).
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Optogenetics provides more specific neuron targeting with high temporal resolution. This light-guided
technology has been used in the PD field to study movement, dopaminergic neuron transplantation and
pathological circuitry. To understand the role of dopamine in movement, Howe and Dombeck used 2-
photon intracellular calcium (by expressig green fluorescent protein (GFP)-Calmodulin fusion protein 6f
(GCaMP6f) in dopaminergic neurons) recording of dopaminergic neurons (DA) projecting to the dorsal
striatum during initiation of movement, acceleration, and resting on cylindrical treadmill (Howe and
Dombeck, 2016). The pattern recorded was then simulated with ChR2 optogenetic stimulation of the
dopaminergic neurons. Their findings suggested DA neurons may not be all that are required to initiate or
accelerate movement. However, DA neuron input to the dorsal striatum may be required for motivation
and modulation of movement. This study suggests application of time-precision firing in the transplanted
DA neurons for PD treatment may increase its efficacy.
Dopaminergic neurons derived from human embryonic stem cells have been successfully transplanted in
rodent and non-human primate PD models (Kriks et al., 2011). Using optogenetics with eNpHR3.0 to
interrogate the mechanism of efficacy, transplanted DA neurons were found to release dopamine to the
striatum and enhance medium spiny neuron excitatory post-synaptic potentials (EPSPs) through
modulation of glutamatergic transmission. This is similar to physiologic dopaminergic neuron function
(Steinbeck et al., 2015). A more recent study using Drosophila larvae demonstrated that enhancing DA
neuron activity promoted recovery of PD symptoms (Qi et al., 2017). Therefore, utilization of an
excitatory opsin (i.e., ChR2) to activate transplanted DA neurons may enhance this treatment’s efficacy
through increasing the release of dopamine (Figure 5D).
Optogenetics has also been used to understand the therapeutic mechanism of DBS for PD. In a study using
transgenic mice expressing ChR2 under Thy1 promotor, the mechanism of DBS was determined to be
through activation of afferent neurons projecting from layer 5 of the cortex to the subthalamic nucleus
(Gradinaru et al., 2009). One caveat to this study was that all layer 5 neurons contained ChR2, and since
not all layer 5 neurons project to the subthalamic nucleus, it was not clear whether the behavior
improvement was exclusively through the subthalamus projecting fibers or fibers projecting elsewhere.
Moreover, the region of the cortex providing therapeutic benefit was unclear. To clarify this role, Sanders
and Jaeger (2016) injected adeno-associated virus constructs containing wheat germ agglutinin-Cre
recombinase (WGA-Cre) in the subthalamic nucleus to retrogradely express Cre recombinase (Cre) in the
projections to the subthalamic nucleus followed by injecting a Cre-dependent hChR2-EYFP construct in
layer 5 of primary motor cortex (M1). This resulted in hChR2 expression in M1 layer 5 neurons projecting
to the subthalamic nucleus. Optogenetic stimulation of afferent STN in M1 resulted in improved
bradykinesia and hypokinesia, which clarified that these neurons mediate DBS efficacy in PD.
Optogenetics has also been used to study the neural circuitry involved in PD and levodopa-induced
dyskinesia (LID). In a study by Kravitz et al., ChR2 was used to either activate the direct (D1) or indirect
(D2) pathway using ChR2 (Kravitz et al., 2010). They found stimulation of the indirect pathway with
ChR2 in mice causes bradykinesia, freezing, and decreased locomotion whereas stimulation of the direct
pathway rescued these deficits. Optogenetics has also been used to study dyskinesia, which is an
undesirable side effect from levodopa therapy. Hernandez et al. showed simultaneous stimulation of the
medium spiny neurons of the direct and indirect pathway induced dyskinesia with levodopa (Hernandez et
al., 2017). Moreover, a different study showed striatal cholinergic neurons also play an important role in
regulating LID (Bordia et al., 2016). Interestingly, optogenetic inhibition of subthalamic nucleus was
shown to be effective in treating LID in rat PD models (Fahn, 2000; Yoon et al., 2016). Collectively, these
studies demonstrate optogenetics application to understand current therapies in PD and to dissect
pathological and physiological movement circuitry. Moreover, optogenetics has potential application for
transplanted DA neurons to stimulate their release of dopamine.
Challenges and Future Direction
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A major obstacle in the application of optogenetics is the translation from bench to patient, specifically the
delivery of optogenetic tools in patients. It is an invasive treatment, requiring implantation of an optic fiber
into brain tissue to supply light to activate opsins in deep regions. This implantation poses two potential
risks: 1) overheating from light can induce damage to tissue, and 2) direct introduction of foreign objects
into brain may cause tissue scarring and can become the source of infection by introducing microbes into
the CNS.
To ensure successful clinical optogenetics application one must not overlook the opsin expression level in
the targeted neuron. Several factors must be taken into consideration: 1) a non-invasive method to express
opsins in specific targeted neurons, 2) a method to evaluate opsin expression level in specific targeted
neurons, and 3) the potential risk of opsin, a foreign protein antigen, as autoimmune agent in patients.
Currently, animal studies use viral transfection and transgenic mice. However, these techniques may raise
technical and ethical issues for human application.
Despite the abovementioned challenges, progress has been made in optogenetics translational studies.
Optogenetics has been safely and effectively applied to awake non-human primate rhesus macaques (Han
et al., 2009, 2011). Clinical trials in phases I and II using adeno-associated virus injection have
successfully demonstrated its safety in patients (Bartus et al., 2013; Murphy and Rabkin, 2013; Simonato
et al., 2013). Another remarkable translational effort was the first patient dosed with optogenetics for
retinitis pigmentosa in a clinical trial conducted by RetroSense Therapeutics, which was reported in 2016.
Similar to retinitis pigmentosa, there are many other diseases which do not have effective treatments or
have treatments that are intolerable. Optogenetics has not only helped us discover the pathophysiology of
many neurological diseases, but has also opened the door to use this as a treatment option.
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Figure 1
Optogenetic control of neural activities.
Opsins can be delivered to neurons to either activate or inactivate their activity. (A) Channelrhodopsin-2 is a cation
channel, which is activated by 460 nm wavelength light. Upon activation, influx of sodium (Na ), potassium (K ),
hydrogen (H ), and calcium (Ca ) occurs into the cell and depolarizes the membrane potential. If the membrane potential
reaches the threshold, this can induce an action potential to activate the neuron. (B) Halorhodopsin is a chloride pump,
which is activated by 570 nm wavelength light. Upon activation, halorhodopsin pumps chloride into the cell to
hyperpolarize the membrane potential, essentially inactivating the neuron.
+ +
+ 2+




Wireless delivery of light allows for more natural mobility of the rodent. (A) Optogenetic stimulation using blue light. The
blue light scattering may prevent control of neurons in deep locations in the brain. (B) The application of red-shifted
opsins. Using light with longer wavelength to activate opsins will reduce light scattering and allow targeting of deeper
brain locations. (C) An alternative strategy to target deeper brain structures. Although more invasive, optic fibers allow
the targeting of deeper brain structures by implanting the fiber near the region of interest.
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Figure 3
Augmenting intracellular calcium signalling to induce axon regeneration.
After axon transection, calcium signalling has been shown to be very important in generation of the growth cone and
promoting axon regeneration through a cascade of events. Optogenetics can be used to augment calcium signalling by
inducing membrane depolarization and opening voltage-gated calcium channels. Calcium 1) alters gene expression
through Ca /calmodulin-dependent protein kinase (CaMK) and mitogen-activated protein kinase (MAPK)
phosphorylation of cAMP response element binding (CREB) protein, 2) activates proteases such as calpains, which then
cleave spectrin and actin to reduce membrane tension to allow the membrane to seal, 3) promotes vesicle fusion to the
spectrin free plasma membrane, and 4) activates delta-like homolog 1 (DLK-1), which promotes retrograde signalling to
the soma to alter gene expression via mitogen-activated protein kinase (MAPK).
2+
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Figure 4
Optogenetics promotes recovery following central nervous system injury.
Previous studies have shown that optogenetics can be used to control denervated motor neurons controlling respiratory
function following spinal cord injury (A) and aid in functional recovery after stroke (B). (C) Schematic drawing shows
neural connections in the central nervous system before injury. (D) Upstream axotomy leads to denervation of distal
axons. Optogenetic stimulation around the lesion site has been shown to enhance neuroplasticity (E) and increase
neurotrophic factors (F) in a stroke model. NGF: Nerve growth factor; GAP43: growth associated protein 43; NTF3:
neurotrophin 3; BDNF: brain-derived neurotrophic factor.
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Figure 5
Application of optogenetics in other neurological disorders.
(A) Enhancing neuronal activity with optogenetics has been shown to increase myelination and oligodendrocyte precursor
proliferation. (B) Optogenetics has been used to treat neocortical, thalamocortical, and temporal lobe epilepsy in rodent
models. (C) Activating dentate gyrus memory engram cells in AD mouse models with optogenetics has been shown to
improve long-term memory by increasing dendritic spine density. (D) Optogenetics is capable of controlling dopamine
release into the striatum from transplanted dopaminergic neurons in Parkinson’s disease.
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